EUVIMEDEUVIMED entdecken
Crossref

Psychotropic comedication trends in long-term lithium treatment for older adults with bipolar disorder: A 10-year analysis

Olaf Paans, Jay L Tilborg, Astrid M Kamperman, Ralph W Kupka, Rob M Kok

Journal of Affective Disorders · 2025

DOI: 10.1016/j.jad.2025.03.091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Olaf Paans und 4 weiteren Autor:innen. Beteiligte Einrichtung: Parnassia Group, Rotterdam, the Netherlands. Electronic address: o.paans@anteszorg.nl. Hauptthemen laut MEDLINE: Bipolar Disorder, Antipsychotic Agents, Lithium Compounds, Psychotropic Drugs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The prescription of psychotropic comedications in patients with bipolar disorder (BD) evolved between 1995 and 2010. This study provides a comprehensive overview of prescription trends across various classes of psychotropic comedications, alongside lithium treatment, in older adults (aged ≥55 years) with BD, from 2010 to 2019. METHODS: This naturalistic, retrospective cohort study included 166 older adults (mean age 67.4 years) treated with lithium. Medical files from a large mental healthcare provider in the Netherlands were used to construct Lifecharts. The average proportion of time that different classes of comedications were prescribed during follow-up was calculated. RESULTS: Patients received psychotropic comedications next to lithium for 75.8 % of total follow-up time. Benzodiazepines were prescribed for 56.2 % of follow-up time, antidepressants for 31.6 %, atypical antipsychotics for 25.9 %, a second mood stabilizer for 18.4 %, and typical antipsychotics for 8.7 %. Most classes of comedications did not show significant changes in prescription trends over the 10-year observation period. Quetiapine at doses below 50 mg/day was prescribed significantly more over time (p = .033), its prescription duration increasing from 2.0 % of total follow-up time in 2010 to 8.1 % in 2019. LIMITATIONS: Generalizability is limited due to focus on older lithium-treated BD patients, potential selection bias, and retrospective design. CONCLUSIONS: Long-term lithium treatment in older adults is mostly combined with other psychotropic medications. Frequent and prolonged use of benzodiazepines and significant increase of low-dose quetiapine use are concerning, given their adverse effects and lack of long-term efficacy. Prescription trends observed before 2010 have largely stabilized. PLAIN LANGUAGE SUMMARY: In this study, we examined what types of comedication were used alongside lithium in older adults with bipolar disorder between 2010 and 2019. For this purpose, we reviewed the medical records of 166 patients 55 years or older in the Netherlands. These patients were prescribed additional psychotropic medications along with lithium 75.8 % of the time. Benzodiazepines, often used to treat anxiety and sleep issues but not recommended for long-term use due to adverse effects, were the most frequently prescribed, namely 56.2 % of the time. Antidepressants were prescribed 31.6 % of the time, atypical antipsychotics 25.9 %, a second mood stabilizer 18.4 %, and typical antipsychotics 8.7 %. Although most prescription trends remained stable between 2010 and 2019, prescription time of low-dose quetiapine increased. We conclude that lithium maintenance treatment is mostly combined with other psychotropic comedications in older adults with bipolar disorder. Considering their potential adverse effects and lack of long-term benefits, the increasing use of low-dose quetiapine and the frequent long-term use of benzodiazepines are particularly concerning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderAntipsychotic AgentsLithium CompoundsPsychotropic DrugsAntimanic AgentsPractice Patterns, Physicians'HumansMaleAgedRetrospective StudiesFemaleMiddle AgedDrug Therapy, CombinationNetherlandsAntidepressive AgentsBenzodiazepines

Stichwörter der Autor:innen

BenzodiazepinesBipolar disorderGeriatric psychiatryLithiumOlder adultsPolypharmacyPrescription trendsPsychotropic comedicationQuetiapine

Substanzen

Antipsychotic AgentsLithium CompoundsPsychotropic DrugsAntidepressive AgentsBenzodiazepinesAntimanic Agents

Autor:innen und Institutionen

  • Parnassia Group, Rotterdam, the Netherlands. Electronic address: o.paans@anteszorg.nl.
  • Parnassia Group, Rotterdam, the Netherlands. Electronic address: j.tilborg@anteszorg.nl.
  • Erasmus Medical Center, Rotterdam, the Netherlands; Epidemiological and Social Psychiatric Research Institute (ESPRi), Department of Psychiatry, Erasmus University Medical Center, Rotterdam, the Netherlands. Electronic…
  • Amsterdam University Medical Center, Vrije Universiteit, dept. of Psychiatry, Amsterdam, the Netherlands. Electronic address: r.kupka@amsterdamumc.nl.
  • Parnassia Group, Department of Old Age Psychiatry, The Hague, the Netherlands. Electronic address: R.Kok@parnassia.nl.

Zitieren

APA

Paans, O., Tilborg, J. L., Kamperman, A. M., Kupka, R. W., & Kok, R. M. (2025). Psychotropic comedication trends in long-term lithium treatment for older adults with bipolar disorder: A 10-year analysis. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.03.091

Vancouver

Paans O, Tilborg JL, Kamperman AM, Kupka RW, Kok RM. Psychotropic comedication trends in long-term lithium treatment for older adults with bipolar disorder: A 10-year analysis. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.03.091

BibTeX
@article{Paans2025,
  author = {Paans, Olaf and Tilborg, Jay L and Kamperman, Astrid M and Kupka, Ralph W and Kok, Rob M},
  title = {Psychotropic comedication trends in long-term lithium treatment for older adults with bipolar disorder: A 10-year analysis},
  journal = {Journal of Affective Disorders},
  year = {2025},
  doi = {10.1016/j.jad.2025.03.091}
}
Kostenlos starten →